Kymenlaakson keskussairaala
- Address
- Kotkantie 41, 48210 Kotka, Finland
Kymenlaakson keskussairaala - Oncology Research Center
Kymenlaakson keskussairaala is a clinical research facility actively engaged in advancing cancer treatment through participation in innovative oncology trials. The center demonstrates expertise in both solid tumor and hematological malignancy research, contributing to evidence-based approaches in cancer care across diverse patient populations.
- Metastatic and locally advanced colorectal cancer: Population-based studies evaluating resectability and surgical outcomes
- Multiple myeloma: Phase 3 trials investigating novel bispecific antibody combinations in newly diagnosed patients
- Translational oncology: Assessment of treatment efficacy through minimal residual disease monitoring and survival analysis
The center's research portfolio emphasizes real-world clinical behavior assessment in metastatic colorectal cancer, including comprehensive evaluation of postoperative morbidity and resection outcomes. In hematologic oncology, the facility participates in cutting-edge trials examining elranatamab-based combinations with daratumumab and lenalidomide for transplant-ineligible multiple myeloma patients, focusing on progression-free survival and minimal residual disease as key efficacy endpoints.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1HUS-yhtymae2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1HUS-yhtymae2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kymenlaakson keskussairaala
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Clinical Behavior, Resectability, and Survival in Metastatic Colorectal Cancer with Fluorouracil and Capecitabine Therapy | HUS-yhtymae | Phase III | Recruiting | Jan 2025 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bortezomib | 1 | Unknown | 2022-11-14 | 2022-11-14 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.